Abstract: The present invention relates to an L-arginine producing mutant strain, and a method for fabricating the same. In particular, the present invention relates to a polynucleotide comprising an argD2 gene (Ncgl2355) that is a putative gene of acetylornithine aminotransferase involved in arginine biosynthesis of Corynebacterium glutamicum, a polypeptide encoded by the polynucleotide, a recombinant vector comprising the polynucleotide, a transformant capable of producing L-arginine in a high yield, which is prepared by introducing the recombinant vector into an L-arginine producing host microorganism to overexpress the argD2 gene, and a method for producing L-arginine by culturing the transformant. The transformant of the present invention overexpresses the argD2 gene to produce L-arginine in a high yield, thereby being used in medicinal and pharmaceutical industries.

Abstract: A method for producing L-threonine using a microorganism is provided. In the method, the threonine dehydratase (tdc) gene existing in the genomic DNA of the microorganism is partially deactivated using a recombination technique. For a microorganism strain with enhanced activity of threonine operon-containing enzymes and the phosphoenolpyruvate carboxylase (ppc) gene, the tdc gene engaged in one of the four threonine metabolic pathways is specifically deactivated, thereby markedly increasing the yield of L-threonine.

Abstract: The present invention relates to a novel endonuclease enzyme which is secreted from immune cell and recognizes bacterial DNA as foreign agent and processes it to produce about 10 bp single-stranded oligonucleotide including CpG motif which is involved in immune response. Also, the present invention relates to a process for producing the endonuclease which comprises culturing human B-lymphoblastic IM9 cell line or TPA-treated myelogenous U937 cell line on an appropriate medium to produce the said endonuclease and isolating the said endonuclease from the cell lysate or the culture medium. In addition, the present invention relates to an immune adjuvant comprising about 10 bp single-stranded oligonucleotide having CpG motif produced by treatment of bacterial DNA by the endonuclease.

Abstract: The present invention relates to a novel microorganism, Corynebacterium ammoniagenes strain CJIP009 having Accession No. KCCM-10226, which is capable of producing 5?-inosinic acid and a process for producing 5?-inosinic acid using the same.

Abstract: The present invention provides novel microorganisms, Brevibacterium lactofermentum CJJA21 (Accession No. KCCM-10222), which is resistant to sodium azide, and Brevibacterium lactofermentum CJJA22 (Accession No. KCCM-10223), which is resistant to ?-aminobutyric acid. These microorganisms are capable of producing L-glutamine in a higher yield than the known strains. The present invention further provides processes for producing L-glutamine using the microorganisms of the invention.

Abstract: The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.

Abstract: Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) ? subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.

Abstract: The present invention relates to extracts derived from Pueraria mirifica, Butea superba and/or Mucuna colletti and extraction thereof, foods, beverages, pharmaceutical products and/or cosmetics containing the extracts as an active ingredient and manufacturing thereof. The extracts isolated from the said plants contain higher concentration of isoflavones. The products products produced from composition containing the extracts considerably increase a resilience an gloss of skin at its application in human body.

Abstract: A method of producing L-threonine using a microorganism is provided, one or more copies of each of the phosphoenolpyruvate carboxylase gene and the threonine operon are additionally intedgrated into a particular site of the chromosomal DNA of the microorganism, whiel its inherent phophoenolpyruvate carboxylase gene and threonine operon remain.

Abstract: Disclosed are a Coryneform bacterium having resistance to an antibiotic, monensin, and producing L-lysine, and a process for producing L-lysine by a direct fermentation, which comprises culturing said microorganism in a fermentation medium, accumulating L-lysine in the resulting culture broth, and recovering L-lysine therefrom.

Abstract: The present invention relates to a Vibrio metscnikovii variants, more particularly to a biochemical characteristics of protease which is obtained from Vibrio metscnikovii variant strains such as Vibrio metschnikovii KS1, Vibrio metschnikovii KS1 transformed with pDSBCm, Vibrio metschnikovii KS1 transformed with pSBCm and Vibrio metschnikovii RH530 N-4-8 strain, the mother strain of Vibrio metschnikovii and to a detergent composition including the protease.

Abstract: The present invention provides novel microorganisms, Brevibacterium lactofermentum CJJA21 (Accession No. KCCM-10222), which is resistant to sodium azide, and Brevibacterium lactofermentum CJJA22 (Accession No. KCCM-10223), which is resistant to ?-aminobutyric acid. These microorganisms are capable of producing L-glutamine in a higher yield than the known strains. The present invention further provides processes for producing L-glutamine using the microorganisms of the invention.

Abstract: A novel alkaline protease VapK suitable for a laundry detergent is disclosed. The gene vapk coding for the protease VapK, the recombinant plasmids containing said gene, and the transformed V. metshnikovii KS1 (pSBCm) with said recombinant plasmid are also disclosed. In addition, a process for producing the protease VapK is disclosed.

Abstract: The present invention relates to a novel endonuclease enzyme which is secreted from immune cell and recognizes bacterial DNA as foreign agent and processes it to produce about 10 bp single-stranded oligonucleotide including CpG motif which is involved in immune response. Also, the present invention relates to a process for producing the endonuclease which comprises culturing human B-lymphoblastic IM9 cell line or TPA-treated myelogenous U937 cell line on an appropriate medium to produce the said endonuclease and isolating the said endonuclease from the cell lysate or the culture medium. In addition, the present invention relates to an immune adjuvant comprising about 10 bp single-stranded oligonucleotide having CpG motif produced by treatment of bacterial DNA by the endonuclease.

Abstract: The present invention relates to a novel endonuclease enzyme which is secreted from immune cell and recognizes bacterial DNA as foreign agent and processes it to produce about 10 bp single-stranded oligonucleotide including CpG motif which is involved in immune response. Also, the present invention relates to a process for producing the endonuclease which comprises culturing human B-lymphoblastic IM9 cell line or TPA-treated myelogenous U937 cell line on an appropriate medium to produce the said endonuclease and isolating the said endonuclease from the cell lysate or the culture medium. In addition, the present invention relates to an immune adjuvant comprising about 10 bp single-stranded oligonucleotide having CpG motif produced by treatment of bacterial DNA by endonuclease.

Abstract: The invention relates to recombinant plasmid pDSBCm harboring the gene vapk-repeated region, which gene encodes alkalic protease VapK, a microorganism Vibrio metschnikovii transformed therewith, and method for producing an alkaline protease VapK using the same microorganism.

Abstract: The present invention relates to a trehalose-producing microorganism and a process for producing trehalose. It also to a novel trehalose synthase protein, a trehalose synthase gene, recombinant plasmids carrying said trehalose synthase gene, and transformed microorganism with said recombinant plasmids.

Abstract: The present invention relates to a novel 3,4-dihydro-1H-naphthalene derivative having a structure of formula 1 or formula 2, its pharmaceutically acceptable salts and their geometric isomers as a highly selective cyclooxygenase-2 inhibitor. Wherein R1, R2, X, A and Q are defined in this specification respectively.

Abstract: The present invention relates to extracts derived from Pueraria mirifica, Butea superba and/or Mucuna colletti and extraction thereof, foods, beverages, pharmaceutical products and/or cosmetics containing the extracts as an active ingredient and manufacturing thereof. The extracts isolated from the said plants contain higher concentration of isoflavones. The products products produced from composition containing the extracts considerably increase a resilience an gloss of skin at its application in human body.

Abstract: A pharmaceutical composition for prevention or treatment of premature ejaculation and/or hypersensitivity of sexual stimulation is provided, which contains a therapeutically effective amount of a purified essence of Bufonis venenum for prevention or treatment of dysspermia or the symptom of non-controlled ejaculation in male, due to premature ejaculation and/or hypersensitivity of sexual stimulation. The Bufonis venenum may be a purified essence of Bufonis venenum extracted by use of one or more organic solvent selected from a group consisting of ethyl acetate, dichloromethane or chloroform, and concentrated, and is purified and fractionated by use of silica gel column. The composition may be formulated in a pharmaccutically acceptable formulation of ointment, suspension, gel, spray, patch or solution.